Existing users Log In New users Sign up

Clinical Uses of Membrane Lipid Replacement Supplements

DISCOVERIES (ISSN 2359-7232), 2016, January-March issue


Nicolson GL, Rosenblatt S, Ferreira de Mattos G, Settineri R, Breeding PC, Ellithorpe RR, Ash MEClinical Uses of Membrane Lipid Replacement Supplements in Restoring Membrane Function and Reducing Fatigue  in Chronic Diseases and Cancer. Discoveries 2016, Jan-Mar; 4(1): e54. DOI: 10.15190/d.2016.1

Submitted: February 4th, 2016Revised: February 10th, 2016Accepted: February 15th, 2016Published: February 18th, 2016;

 GO BACK to 2016, January-March issue


Clinical Uses of Membrane Lipid Replacement Supplements in Restoring Membrane Function and Reducing Fatigue  in Chronic Diseases and Cancer

Garth L. Nicolson (1,*), Steven Rosenblatt (2), Gonzalo Ferreira de Mattos (3), Robert Settineri (4), Paul C. Breeding (5), Rita R. Ellithorpe (6), Michael E. Ash (7)

(1) The Institute for Molecular Medicine, Huntington Beach, California 92647, USA;

(2) Saint John’s Health Center, Santa Monica, CA, USA;

(3) Laboratory of Ion Channels, School of Medicine, Universidad de la República, Montevideo, Uruguay,

(4) Sierra Productions Research, Irvine, CA, USA;

(5) Blue Hole Wellness, Wimberley, TX, USA;

(6) Tustin Longevity Center, Tustin, CA, USA;  

(7) Clinical Education, Newton Abbot, Devon, UK.

*Correspondence to: Prof. Emeritus Garth L. Nicolson, PhD, MD (H), Department of Molecular Pathology, The Institute for Molecular Medicine, P.O. Box 9355, S. Laguna Beach, CA 92652; Email: gnicolson@immed.org; Website: www.immed.org


Membrane Lipid Replacement is the use of functional oral supplements containing cell membrane glycerolphospholipids and antioxidants to safely replace damaged membrane lipids that accumulate during aging and in various chronic and acute diseases.  Most if not all clinical conditions and aging are characterized by membrane phospholipid oxidative damage, resulting in loss of membrane and cellular function.  Clinical trials have shown the benefits of Membrane Lipid Replacement supplements in replenishing damaged membrane lipids and restoring mitochondrial function, resulting in reductions in fatigue in aged subjects and patients with a variety of clinical diagnoses.  Recent observations have indicated that Membrane Lipid Replacement can be a useful natural supplement strategy in a variety of conditions: chronic fatigue, such as found in many diseases and disorders; fatiguing illnesses (fibromyalgia and chronic fatigue syndrome); chronic infections (Lyme disease and mycoplasmal infections); cardiovascular diseases; obesity, metabolic syndrome and diabetes; neurodegenerative diseases (Alzheimer’s disease); neurobehavioral diseases (autism spectrum disorders); fertility diseases; chemical contamination (Gulf War illnesses); and cancers (breast, colorectal and other cancers).  Membrane Lipid Replacement provides general membrane nutritional support during aging and illness to improve membrane function and overall health without risk of adverse effects.

Access full text of the manuscript here: 


1. Nicolson GL. Lipid replacement as an adjunct therapy in chronic fatigue, anti-aging and restoration of mitochondrial function. J. Am. Nutraceut. Assoc. 2003; 6(3): 22-28.

2. Nicolson GL, Ash ME. Lipid Replacement Therapy: a natural medicine approach to replacing damaged lipids in cellular membranes and organelles and restoring function.  Biochim, Biophys. Acta 2014; 1838: 1657-1679.

3. Nicolson GL. Lipid replacement therapy: a nutraceutical approach for reducing cancer-associated fatigue and the adverse effects of cancer therapy while restoring mitochondrial function.  Cancer Metastasis Rev. 2010; 29(3), 543-552.

4. Nicolson GL.  Membrane Lipid Replacement: clinical studies using a natural medicine approach to restoring membrane function and improving health. Intern. J. Clin. Med. 2016; 7: in press.

5. Küllenberg D, Taylor LA, Schneider M, Massing  U. Health effects of dietary phospholipids. Lipids Health Dis. 2012; 11: e3.

6. van Meer G, Voelker DB, Feigenson GW.  Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 2008; 9: 112-124.

7. Escribá PV.  Membrane-lipid therapy: a new approach in molecular medicine. Trends Mol. Med. 2006; 12, 34-43.

8. Ibarguren M, López DJ, Escriba PV.  The effect of natural and synthetic fatty acids on membrane structure, microdomain organization, cellular functions and human health. Biochim.  Biophys. Acta 2014; 1838: 1518-1528.

9. Dobbins WO III. Morphologic aspects of lipid absorption. Am. J. Clin. Nutr. 1969; 22: 257-265.

10. Zierenberg O, Grundy SM. Intestinal absorption of polyenephosphatidylcholine in man. J. Lipid Res. 1982; 23: 1136-1142.

11. Gundermann KJ, Kuenker A, Kuntz E, Drozdzik M.  Activity of essential phospholipids (EPL) from soybean in liver diseases.  Pharmacol. Rep. 2011; 63: 643-659.

12. Le Kim D, Betzing H.  Intestinal absorption of polyunsaturated phosphatidylcholine in the rat.  Hoppe Seylers Zeit. Physiol. Chem. 1976; 357: 1321-1331.

13. Liao TH, Hamosh P, Hamosh M. Fat digestion by lingual lipase: mechanism of lipolysis in the stomach and upper small intestine. Pediatric Res. 1984; 18: 402-409.

14. Adibhatla RM, Hatcher JF.  Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 2010; 12: 125-169.

15. Catalá A.  Lipid peroxidation modifies the picture of membranes from the “Fluid Mosaic Model” to the “Lipid Whisker Model.” Biochimie 2012; 94: 101-109.

16. Wagener HH, Fontaine R, Neumann B.  Pharmakologie “essentiele” phospholipide (EPL). Drug Res. 1976; 26: 1733-1743.

17. Gundermann KJ.  The “essential” phospholipids as membrane therapeutic. European Society of Biochemical Pharmacology, 1993, Szczecin, Poland.

18. Pandey NR, Sparks DL.  Phospholipids as cardiovascular therapeutics. Curr. Opin. Invest. Drugs 2008; 9(3), 281-285.

19. Ellithorpe RR, Settineri R, Ellithorpe T,  Nicolson GL. Blood homocysteine and fasting insulin levels are reduced and erythrocyte sedimentation rates are increased with a glycophospholipid-vitamin formulation: a retrospective study in older subjects. Funct. Foods Health Dis. 2015; 5(4): 126-135.

20. Cohn JS, Wat E, Kamili A, Tandy S.  Dietary phospholipids, hepatic metabolism and cardiovascular disease. Curr. Opin. Lipidol. 2008; 19: 257-262.

21. U. S. Federal Drug Administration.  Scientific literature reviews on generally recognized as safe (GRAS) food ingredients: Lecithins.  GRAS Report, 1970; PB-241 970.

22. Hendry GAF.  Evolutionary origins and natural functions of fructans—a climatological, biogeographic and mechanistic appraisal. New Phytol. 1993; 123: 3-14.

23. Nicolson GL, Settineri R, Ellithorpe R.  Lipid Replacement Therapy with a glycophospholipid formulation with NADH and CoQ10 significantly reduces fatigue in intractable chronic fatiguing illnesses and chronic Lyme disease. Intern. J. Clin. Med. 2012; 3: 163-170.

24. Nicolson GL.  Mitochondrial dysfunction and chronic disease: treatment with natural supplements. Altern. Ther. Health Med. 2014; 20(Suppl 1): 18-25.

25. Jorissen BL, Brouns F, van Boxtel MP, Ponds RW, Verhey FR, Jolles J, Riedel WJ.  The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment.  Nutr. Neurosci. 2001; 4: 121-134.

26. Morrison JD.  Fatigue as a presenting complaint in family practice. J. Family Pract. 1980; 10: 795-801.

27. Kroenke K, Wood DR, Mangelsdorff AD, Meier NJ, Powell JB.  Chronic fatigue in primary care.  Prevalence, patient characteristics, and outcome. JAMA 1988; 260: 929-934.

28. Filler K, Lyon D, Bennett J, McCain N, Elswick R, Lukkahatai N, Saligan LN. Association of mitochondrial dysfunction and fatigue: a review of the literature. BBA Clin. 2014; 1: 12-23.

29. Krupp LB, Pollina DA.  Mechanisms and management of fatigue in progressive neurological disorders. Curr. Opin. Neurol. 1996; 9: 456-460.

30. Myhill S, Booth NE,  McLaren-Howard J.  Chronic fatigue syndrome and mitochondrial dysfunction. Intern. J. Clin. Expl. Med. 2009; 2: 1-16.

31. Brown LF, Kroenke K.  Cancer-associated fatigue and its association with depression and anxiety: a systematic review.  Psychosomat. 2009; 50: 440-447.

32. Manuel y Keenoy B, Moorkens G, Vertommen J, De Leeuw I.  Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Sci. 2001; 68: 2037-2049.

33. Fulle S, Mecocci P, Fano G, Vecchiet I, Racciotti D, Cherubini A, Pizzigallo E, Vecchiet L, Senin U, Beal MF.  Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Rad. Biol. Med. 2000; 29: 1252-1259.

34. Pall ML.  Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med. Hypoth. 2000; 54: 115-125.

35. Richards RS, Roberts TK, McGregor NR, Dunstan RH, Butt HL.  Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep. 2000; 5: 35-41.

36. Ellithorpe RR, Settineri R, Nicolson GL.  Reduction of fatigue by use of a dietary supplement containing glycophospholipids.  J. Am. Nutraceut. Assoc. 2003; 6(1): 23-28.

37. Agadjanyan M, Vasilevko V, Ghochikyan A, Berns P, Kesslak P, Settineri R, Nicolson GL. Nutritional supplement (NTFactor) restores mitochondrial function and reduces moderately severe fatigue in aged subjects.  J. Chronic Fatigue Syndr. 2003; 11(3): 23-36.

38. Nicolson GL, Ellithorpe R.  Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial function and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses. J. Chronic Fatigue Syndr. 2006; 13(1), 57-68.

39. Ellithorpe RA, Settineri R, Jacques B, Nicolson GL.  Lipid Replacement Therapy functional food with NTFactor for reducing weight, girth, body mass, appetite, cravings for foods and fatigue while improving blood lipid profiles. Funct. Foods Health Dis. 2012; 2(1): 11-24.

40. Nicolson GL, Ellithorpe RR, Ayson-Mitchell C, Jacques B, Settineri R.  Lipid Replacement Therapy with a glycophospholipid-antioxidant-vitamin formulation significantly reduces fatigue within one week. J. Am. Nutraceut. Assoc. 2010; 13(1): 11-15.

41. Nicolson GL, Settineri R, Ellithorpe RR.  Lipid Replacement Therapy with a glycophospholipid formulation containing NADH and CoQ10 significantly reduces fatigue and improves mood and cognition in intractable chronic fatiguing illnesses and chronic Lyme disease.  Townsend Lett. 2012; 347(6): 58-61.

42. Nicolson GL, Settineri R, Ellithorpe RR.  Glycophospholipid formulation with NADH and CoQ10 significantly reduces intractable fatigue in Western blot-positive chronic Lyme disease patients: preliminary report. Funct. Foods Health Dis. 2012; 2(3): 35-47.

43. Piper BF, Linsey AM, Dodd MJ.  Fatigue mechanism in cancer. Oncol. Nurs. Forum 1987; 14:17-23.

44. Nicolson GL, Conklin KA. Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by Molecular Replacement Therapy. Clin. Expl. Metastasis 2008; 25: 161-169.

45. Colodny L, Lynch K, Farber C, Papish R, Phillips K, Sanchez M, Cooper K, Pickus O, Palmer D, Percy TB, Faroqui M, Block JB.  Results of a study to evaluate the use of Propax to reduce adverse effects of chemotherapy.  J. Am. Nutraceut. Assoc. 2001;  3(1): 17-25.

46. Nicolson GL, Settineri R, Ellithorpe RR.  Neurodegenerative and fatiguing illnesses, infections and mitochondrial dysfunction: the use of natural supplements to improve mitochondrial function.  Funct. Foods Health Dis. 2014; 4(1): 23-65.

47. Nicolson GL. Metabolic syndrome and mitochonrial function: molecular replacement and antioxidant supplements to prevent membrane oxidation and restore mitochondrial function. J. Cell. Biochem. 2007; 100: 1352-1369.

48. Nicolson GL, Berns P, Nasralla M, Haier J, Nicolson NL, Nass M. Gulf War Illnesses: chemical, radiological and biological exposures resulting in chronic fatiguing illnesses can be identified and treated. J. Chronic Fatigue Syndr. 2003; 11(1): 135-154.

49. Ellithorpe RR, Settineri R, Mitchell CA, Jacques B, Ellithorpe T, Nicolson  GL.  Lipid replacement therapy drink containing a glycophospholipid formulation rapidly and significantly reduces fatigue while improving energy and mental clarity.  Funct. Foods Health Dis. 2011; 1(8): 245-254.

50. Richter Y, Herzog Y, Lifshitz Y, Hayun R, Zchut S.  The effect of soybean phosphatidylserine on cognitive performance in elderly with subjective memory complaints: a pilot study. Clin. Intervent. Aging 2013; 8: 557-563.

51. Kato-Kataoka A, Sukai M, Ebina R, Nonaka C, Asano T, Miyamori T. Soybean-derived phosphatidylserine improves memory function of elderly Japanese subjects with memory complaints. J. Clin. Biochem. Nutr. 2010; 47: 246-255.

52. Cernacchi T, Bertoldin T, Farina C, Flori MG. Crepaldi G.  Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on the efficacy of phosphatidylserine administration. Aging (Milano) 1993; 5: 123-133.

News & Events Latest news from Discoveries

  • 2022, April| AWARDS!

    2022 Discoveries Award winning articles!

    - Kinal Bhatt et al. 2021 (Larking Health System, FL, USA); Bhatt K, Agolli A, Patel MH, et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries. 2021;9(1):e126. 
    27 citations in the past 1 year - $1000 prize

    - Hasnain Jan et al. 2020 (Quaid-i-Azam University, Pakistan); Jan H, Faisal S, Khan A, et al. COVID-19: Review of Epidemiology and Potential Treatments Against 2019 Novel Coronavirus. Discoveries. 2020;8(2):e108. 
    23 citations in the past 2 years - $400 prize

    Congratulations! Prizes will be received by the awardees in July 2022!

  • 2021, July| 2021, Jul-September

    Due to the high volume of the submitted articles, both Discoveries and Discoveries Reports are experiencing processing and publication delays during the months of July-September 2021. We will get back to the normal processing and publication times starting in October 2021. Note that our editorial and administrativ work is fully funded by our publishing house at this time and we are striving to KEEP THE NO FEE/NO CHARGE strategy in place as long as possible. 

  • 2021, January| AWARDS!

    2022 DISCOVERIES AWARDS! Discoveries will offer $1000 and $400 awards in early 2022, for the most cited (2021 ISI Citations) and visible articles published in 2018-2021.

  • 2020, November| Follow us on Twitter!

    You can now follow the latest Discoveries news and updates on Twitter! (@DiscoveriesNews) 

  • 2020, August| For Authors!

    Due to a high volume of article submissions, our peer-review process takes more than usual. The pre-screening decision is released in 1-2 days, while the peer-review process lasts between 10 and 20 days.  

  • 2020, April | For Authors!

    WE DO NOT TOLERATE ANY MISCONDUCT! Please be aware that we are testing all received articles with specialized software for PLAGIARISM and WE WILL TAKE MEASURES if your article is already published or in consideration for publication by other journals! This may result in serious professional consequences for the authors. The latest striking case is the following article which is already published and was re-submitted here.  

  • 2020, April | For Authors!

    We are happy to let you know that all articles published in Discoveries are now included in PubMedCentral (PMC). New accepted articles will be included in PMC and PubMed within 1-2 weeks after their publication.

  • 2020, January | For Authors!

    Starting in January 2020, Discoveries will also consider articles submitted by Discoveries' Editorial Board members. However, only a small number of such articles (maximum 4 articles/year) will be considered for publication after the peer-review process, and the authors who are also our editors will be clearly disclosed on our website.  

  • 2019, September | Indexed by PMC

    Discoveries is now indexed by PubMedCentral and Pubmed. The agreement with US National Library of Medicine was signed on September 10, 2019. Our next step is ISI Web of Science indexing. NOTE: previously published articles will be included on PubMed in early 2020.

  • 2019, September | PubMed inclusion!

    We are happy to let you know that Discoveries successfuly passed the last step (Technical Review) required for PubMedCentral and PubMed inclusion!

  • 2019, July | PubMed inclusion News!

    We are happy to receive positive comments from PMC/NLM-NIH regarding Discoveries' last step (Technical Review) required for PubMedCentral and PubMed inclusion. We will let you know once whole indexing process is completed. 

  • 2019| Sharing and Distribution!

    All articles published in Discoveries are Open Access articles distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and it is not used for commercial purposes.

  • 2018-2019 | For Authors!

    From now on and for at least 1 year, we will only accept articles from authors that are NOT members of Discoveries' Editorial Board. All articles submitted by our editors will be immediately rejected until further notice (one accepted article was already rejected). 

  • 2018 | PubMed inclusion News!

    Discoveries successfully passed the Scientific Quality Review by NLM-NIH for PubMedCentral and PubMed indexing. This is the first and the most important step towards PubMedCentral and PubMed indexing! The second (last) step is the Technical Review.

  • 2016, April | Faster Peer-Review

    Starting on April 13th 2016, all articles selected for a peer-review will receive the post peer-review decision within ~10 days. The initial pre-screening time will remain the same (48h from the submission of the manuscript). This decision will significantly accelerate the publication, with no effect on the quality of the peer-review process.

  • 2016, February | Manuscript submission

    Discoveries is commited to excellence, quality and high editorial standards. We are receiving an increasing number of manuscripts for which the identity of the authors/corresponding author can't be verified. Please NOTE that ALL these articles were and will be immediately REJECTED. Indicating an institutional email address is the easiest way to overcome this problem! Moreover, we do not accept any pressure on our editorial board to accept a manuscript. This results in a prompt rejection of the article.

    Editorial Policies
  • 2016, January | Main Objective

    After reaching all proposed milestones until now (including being indexed by Google Scholar in 2014), Discoveries' next Aim is PubMed indexing of all its articles (already published and upcoming). There will be no charge for the submission or publication of articles before Discoveries is indexed.

  • 2015, August | Discoveries - on PubMed

    We are happy to announce that our first Discoveries articles were included in PMC and PubMed. More articles (submitted by NIH funded authors) are now processed for being included.

    Discoveries articles now on PubMed
  • 2015, April | Special Issue

    DISCOVERIES published the SPECIAL ISSUE entitled "INFLAMMATION BETWEEN DEFENSE AND DISEASE: Impact on Tissue Repair and Chronic Sickness".

    Special Issue on "Inflammation"
  • 2015 | Ischemia Collection

    DISCOVERIES launched a call for papers for a Collection of Articles with focus on "ISCHEMIA". If you are interested to submit a manuscript, please contact us at info@discoveriesjournals.org

  • 2014, September | Special Issue

    DISCOVERIES just publish the SPECIAL ISSUE entitled "CELL SECRETION & MEMBRANE FUSION" in September 2014. Initially scheduled for publication between October 2014-March 2015, this issue was successfully published earlier than scheduled. 

    Special Issue
  • 2014, April | Indexed by Google Scholar

    All our published articles are now indexed by Google Scholar! First citations to Discoveries articles are included! Search for the article's title (recommended) or the authors:

    Google Scholar Search
  • 2014 | DISCOVERIES

    DOIs (Digital Object Identifiers) are now assigned to all our published manuscripts in Discoveries. DOI uniquely identifies an article and is provided by CrossRef.

  • 2013, July | Manuscript Submission

    Submit your manuscript FREE, FAST and EASY ! (in less than 1 minute)! There are NO fees for the manuscript submission or publishing of the accepted manuscripts.
    read more

  • 2013, July | DISCOVERIES

    We are now ACCEPTING MANUSCRIPTS for publishing in DISCOVERIES. We aim publishing a small number of high impact experimental articles & reviews (around 40/year) to maintain a high impact factor. Domains of interest: all areas related to Medicine, Biology and Chemistry ...

    read more
Member Login
Free Registration Click here to sign up
Copyright © 2013 Applied Systems. All Rights Reserved.